Oryzon Genomics SA
MAD:ORY
Oryzon Genomics SA
MAD:ORY
Price:
2.79
EUR
Market Cap:
€222.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Oryzon Genomics SA
MAD:ORY
|
ES |
|
L
|
Lytix Biopharma AS
F:6BG
|
NO |
|
P
|
Phoenix Asia Holdings Ltd
NASDAQ:PHOE
|
HK |
|
T
|
Thunder Bridge Capital Partners IV Inc
NASDAQ:THCP
|
US |
|
Manchester United PLC
NYSE:MANU
|
UK |
|
Titagarh Wagons Ltd
NSE:TWL
|
IN |
|
D
|
Deutsche Effecten und Wechsel Beteiligungsgesellschaft AG
SWB:EFF
|
DE |
|
V
|
Vaiv Company Inc
KOSDAQ:301300
|
KR |
|
Nordic Iron Ore AB
F:NIO
|
SE |
|
W
|
Waldencast Acquisition Corp
NASDAQ:WALD
|
US |
|
L
|
LogicBio Therapeutics Inc
F:0IF
|
US |
Multiples-Based Value
The Multiples-Based Value of one
ORY
stock under the Base Case scenario is
hidden
EUR.
Compared to the current market price of 2.79 EUR,
Oryzon Genomics SA
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ORY Multiples-Based Value
LOCKED
Multiples Across Competitors
ORY Competitors Multiples
Oryzon Genomics SA Competitors
Oryzon Genomics SA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| ES |
|
Oryzon Genomics SA
MAD:ORY
|
216.3m EUR | 0 | -83 | -34.3 | -33.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
369.2B USD | 6 | 88.2 | 14.6 | 20.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.5B USD | 5.1 | 24.3 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173.4B USD | 5.9 | 20.4 | 12.7 | 15.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.4B USD | 9.3 | 28.2 | 21.2 | 22.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.5B USD | 5.6 | 17.9 | 13.3 | 15.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67B AUD | 3.1 | 34 | 11.3 | 14.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.6B EUR | 11.3 | 36.2 | 39.3 | 40.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
